Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, single-arm, feasibility study evaluating eribulin in
combination with capecitabine as an adjuvant chemotherapy regimen in approximately 65
subjects with early-stage (I-II), human epidermal growth factor receptor 2 (HER2)- normal,
estrogen receptor (ER)-positive breast cancer.